Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Inks Another NGS Sample Prep Deal, This Time with NuGen


Caliper Life Sciences continued its recent foray into sample preparation for next-generation sequencing, announcing today an agreement with NuGen to develop and market automated next-gen sequencing sample prep methods on Caliper's Sciclone NGS workstation.

According to the companies, the deal aims to enable researchers to use NuGen's Ovation and Encore reagents on Caliper's liquid-handling platforms to automate processing of a wide range of sample types, such as nucleic acids extracted from sorted cells, fine needle aspirates, formalin-fixed paraffin-embedded tissue, and other limited and compromised clinical samples.

More specifically, Caliper and NuGen will first co-develop automation scripts for NuGen's Ovation RNA-Seq System and Encore Multiplex System I on the Sciclone workstation. The companies said this will enable end-to-end, high-throughput library construction from as little as 500 pg of total RNA.

Caliper and NuGen said that the combined product is scheduled to be available by the end of March.

NuGen CEO Elizabeth Hutt said in a statement that the combined offering allows customers to work from total RNA, which "reduces the bias inherent in the selection steps, and results in a more complete data set and a more comprehensive understanding of the transcriptome, including non-coding RNAs."

The companies noted that the Sciclone NGS workstation can be integrated with Caliper's LabChip GX analytical QC platform and LabChip XT preparative nucleic acid fragmentation platform.

In October, Caliper inked an agreement under which Illumina was to promote the LabChip XT for sample prep in next-gen sequencing applications on Illumina's Genome Analyzer and HiSeq 2000 platforms. The companies also said at the time that they would co-market the LabChip GX for analyzing size, concentration, and integrity of DNA or RNA for quality control during sample prep (PCR Insider, 10/21/10).

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.